Application Based on Phase 1 Study by GC Green Cross

"Securing Vaccine Sovereignty to Strengthen Protection of Public Health Rights"

The National Institute of Health under the Korea Disease Control and Prevention Agency announced on July 24 that it has submitted a Phase 2 clinical trial plan (IND) for a COVID-19 messenger ribonucleic acid (mRNA) vaccine candidate to the Ministry of Food and Drug Safety.


Since April of last year, the Korea Disease Control and Prevention Agency has been supporting non-clinical and clinical projects focusing on institutions possessing core mRNA technologies, through initiatives such as the "Pandemic Preparedness mRNA Vaccine Development Support Project (R&D)." Among these, GC Green Cross applied for the Phase 2 clinical trial plan based on research results from the Phase 1 clinical trial, which was approved in December last year.

KDCA Submits Phase 2 IND for Domestic mRNA COVID-19 Vaccine View original image

The support program is a project that offers assistance from non-clinical stages to Phase 3 clinical trials to develop a domestically produced COVID-19 mRNA vaccine using mRNA technology. Its goal is to secure an mRNA vaccine platform and establish a rapid vaccine development system in the event of future pandemics.


The selection and evaluation process for R&D projects has also been completed. The Korea Disease Control and Prevention Agency plans to begin Phase 2 clinical research projects starting next month, following agreement procedures. Once the clinical trial plan is approved, the agency will conduct clinical tests to verify the safety and immunogenicity of the COVID-19 vaccine candidate in healthy individuals.



Im Seungkwan, Commissioner of the Korea Disease Control and Prevention Agency, stated, "We look forward to securing vaccine sovereignty and strengthening the protection of public health rights through the development of a domestically produced COVID-19 mRNA vaccine," adding, "We will spare no effort in supporting successful research by strengthening cooperation with project institutions and relevant ministries."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing